









Markets
/
Stocks
/
nasdaq-crvo
/

CervoMed Inc

CRVO

5.310USD

+0.710+15.43%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

49.13MMarket Cap

LossP/E TTM



CervoMed Inc

5.310

+0.710+15.43%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of CervoMed Inc

Currency: USD Updated: 2026-02-06

Key Insights

CervoMed Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 140 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 22.43.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

CervoMed Inc's Score

Industry at a Glance

Industry Ranking

140 / 392

Overall Ranking

285 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

CervoMed Inc Highlights

StrengthsRisks

CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.

Growing

The company is in a growing phase, with the latest annual income totaling USD 9.74M.

Fairly Valued

The company’s latest PE is -1.83, at a medium 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 354.95K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.81.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

22.429

Target Price

+387.58%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of CervoMed Inc is 6.08, ranking 292 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 322.57K, representing a year-over-year decrease of 83.37%, while its net profit experienced a year-over-year decrease of 62.54%.

Score

Industry at a Glance

Previous score

6.08

Change



Financials

8.28

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.45

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

CervoMed Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of CervoMed Inc is 6.17, ranking 321 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.83, which is -873.00% below the recent high of 14.14 and -1637.27% above the recent low of -31.77.

Score

Industry at a Glance

Previous score

6.17

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 140/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of CervoMed Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 20.00, with a high of 31.00 and a low of 15.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

22.429

Target Price

+387.58%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

CervoMed Inc

CRVO

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of CervoMed Inc is 7.02, ranking 118 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 7.52 and the support level at 3.80, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.66

Change

0.36

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.159

Sell

RSI(14)

35.771

Neutral

STOCH(KDJ)(9,3,3)

29.363

Buy

ATR(14)

0.532

High Vlolatility

CCI(14)

-42.913

Neutral

Williams %R

70.330

Sell

TRIX(12,20)

-1.817

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

4.856

Buy

MA10

5.177

Buy

MA20

6.124

Sell

MA50

7.483

Sell

MA100

7.642

Sell

MA200

8.032

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of CervoMed Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 45.61%, representing a quarter-over-quarter decrease of 1.84%. The largest institutional shareholder is The Vanguard, holding a total of 354.95K shares, representing 3.84% of shares outstanding, with 11.83% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Boger (Joshua S)

1.06M

AWM Investment Company, Inc.

863.20K

Gregoire (Sylvie L.)

753.29K

+3.08%

Alam (John J)

753.29K

+3.08%

Morgan Stanley & Co. LLC

410.15K

+10.48%

The Vanguard Group, Inc.

Star Investors

343.46K

+1.01%

Zavrl (Frank E.)

353.01K

Millennium Management LLC

71.51K

-6.01%

Geode Capital Management, L.L.C.

64.47K

+18.82%

BlackRock Institutional Trust Company, N.A.

47.76K

-51.05%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of CervoMed Inc is 3.18, ranking 167 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is -0.81. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.